Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKesson
Express Scripts
Baxter
McKinsey

Last Updated: June 29, 2022

Patent: 9,868,972


✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,868,972
Title:Hybrid suppressor tRNA for vertebrate cells
Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA\'s, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA\'s/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided. The present invention provides vertebrate cells with translation components, e.g., pairs of orthogonal aminoacyl-tRNA synthetases (O-RSs) and orthogonal tRNA\'s (O-tRNA\'s) and individual components thereof, that are used in vertebrate protein biosynthetic machinery to incorporate an unnatural amino acid in a growing polypeptide chain, in a vertebrate cell.
Inventor(s): Tian; Feng (San Diego, CA), Norman; Thea (Clinton, WA), Chu; Stephanie (Simi Valley, CA)
Assignee: Ambrx,Inc. (La Jolla, CA)
Application Number:14/820,318
Patent Claims:see list of patent claims

Details for Patent 9,868,972

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 10/28/1982 See Plans and Pricing 2026-09-08
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 12/29/2015 See Plans and Pricing 2026-09-08
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 08/06/1998 See Plans and Pricing 2026-09-08
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 03/31/1994 See Plans and Pricing 2026-09-08
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 05/25/2018 See Plans and Pricing 2026-09-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Mallinckrodt
Merck
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.